Sangamo Biosciences, Inc. (NASDAQ:SGMO)
CAPS Rating:
The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes.
The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes.
Recs
Promising if clinical results go OK